Back to news

Blackstone Life Sciences Announces $750 Million R&D Funding Agreement

Business Wire•16/11/2026•09:00 ET
0

Key Highlights

  • ➤Blackstone will provide Johnson & Johnson $750 million for OLN324 Phase 3 development
  • ➤OLN324 targets wet age-related macular degeneration and diabetic macular edema
  • ➤Funding follows expected Johnson & Johnson acquisition of Ollin Biosciences
  • ➤Blackstone receives regulatory and sales milestones plus single digit royalties

Expert Statements

Nicholas Galakatos, Global Head of Blackstone Life Sciences

“We are pleased to expand our relationship with Johnson & Johnson by supporting the Phase 3 development of OLN324”

Nicholas Galakatos, Global Head of Blackstone Life Sciences

“Our financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients’ lives.”

Kiran Reddy, Senior Managing Director at Blackstone Life Sciences

“OLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients”

Kiran Reddy, Senior Managing Director at Blackstone Life Sciences

“We are excited to work with Johnson & Johnson to help advance this promising new treatment option to patients.”

Blackstone Life Sciences Announces $750 Million R&D Funding Agreement

Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (“Ollin”).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in